New pharmacologic options for renal preservation.
The understanding of the cause and pathophysiology of renal failure has guided the rational development of pharmacologic renoprotective strategies. Although traditionally anesthesiologists have focused on renal hemodynamic derangements, newer information suggests that cellular interactions amplify and perpetuate the insult. Consequently, the potential renoprotective armamentarium not only encompasses the more traditional vasoactive agents but also therapeutic approaches that may modify the cellular response to injury. Although few of these agents have reached the clinical arena, preliminary work suggests that this new approach to renal injury and protection may be promising.
Garwood
S
S
Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut, USA. susan.garwood@yale.edu
D058186:Acute Kidney Injury / Q000503:physiopathology / Q000517:prevention & control*; D000975:Antioxidants / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D011453:Prostaglandins / Q000627:therapeutic use; D020011:Protective Agents / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D000521:alpha-MSH / Q000627:therapeutic use
D000975:Antioxidants; D002121:Calcium Channel Blockers; D018491:Dopamine Agonists; D011453:Prostaglandins; D020011:Protective Agents; D013256:Steroids; D000521:alpha-MSH; D009320:Atrial Natriuretic Factor